Spiber Inc. Competitors

For 80 years Lenzing has been looking beyond fiber. Inspired by the needs of the world, we create smart and exciting solutions made from natural wood – for consumers, for our business partners, and for an environment worth living in. Our expertise and passion are dedicated to support the industry, brands and retailers – in sectors like fashion, beauty care or hygiene – by providing products and services that maximize value creation from both the environmental and the economical perspective. Our tenacity and engineering excellence also drive the development of innovative plant and process technologies around cellulosic fibers and related solutions. Lenzing offers great career opportunities for tech-savvy tinkerers, life-oriented researchers and visionaries with a strong sense of responsibility. Welcome to follow our company on LinkedIn, find out more from our global web sites below or check out our product web site under http://www.tencel.com/ TENCEL™, LENZING™, ECOVERO™, REFIBRA™ and VEOCEL™ are trademarks of Lenzing AG.

PANGAIA is a purpose-driven lifestyle company bringing problem-solving materials science innovations to the world. We are a global collective of one heart and many hands - scientists, technologists, designers – using nature’s intelligence to create apparel from innovative tech and bio-engineered materials powered by nature. Our vision is to inspire and accelerate an earth positive future as we design a business model where our products are better for the planet than if they did not exist. Every product we create is born from science and purpose, each solving an environmental problem of the industry. From the materials we use to the colors we create, we are committed to protecting, preserving and promoting biodiversity on earth, pioneering and using materials that consider the delicate balance between planet, functionality and purpose.

Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients. Bolt’s technology is appropriate for a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer and therefore applicable to many types of patients, including those who are refractory to the current generation of checkpoint inhibitors. The company is led by a team with extensive oncology drug discovery and development experience. Bolt was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit www.boltbio.com.